Trial · NCT03464136
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Clinical Remission at Week 52 | Adalimumab | 61.0 | percentage of participants | ||
| Percentage of Participants With Clinical Remission at Week 52 | Ustekinumab | 64.9 | percentage of participants | ||
| Percentage of Participants With Corticosteroid-free Remission at Week 52 | Adalimumab | 57.4 | percentage of participants | ||
| Percentage of Participants With Corticosteroid-free Remission at Week 52 | Ustekinumab | 60.7 | percentage of participants | ||
| Percentage of Participants With Clinical Response at Week 52 | Adalimumab | 66.2 | percentage of participants | ||
| Percentage of Participants With Clinical Response at Week 52 | Ustekinumab | 72.3 | percentage of participants | ||
| Percentage of Participants in Patient Reported Outcome (PRO)-2 Symptom Remission at Week 52 | Adalimumab | 55.4 | percentage of participants | ||
| Percentage of Participants in Patient Reported Outcome (PRO)-2 Symptom Remission at Week 52 | Ustekinumab | 56.5 | percentage of participants | ||
| Percentage of Participants With Clinical Remission at Week 16 | Adalimumab | 60 | percentage of participants | ||
| Percentage of Participants With Clinical Remission at Week 16 | Ustekinumab | 57.1 | percentage of participants | ||
| Percentage of Participants With Endoscopic Remission at Week 52 | Adalimumab | 30.7 | percentage of participants | ||
| Percentage of Participants With Endoscopic Remission at Week 52 | Ustekinumab | 28.5 | percentage of participants | ||
| Percentage of Participants With Clinical Remission Through Week 52 | Adalimumab | Week 2 | 28.7 | percentage of participants | |
| Percentage of Participants With Clinical Remission Through Week 52 | Ustekinumab | Week 2 | 23.0 | percentage of participants | |
| Percentage of Participants With Clinical Remission Through Week 52 | Adalimumab | Week 8 | 47.7 | percentage of participants | |
| Percentage of Participants With Clinical Remission Through Week 52 | Ustekinumab | Week 8 | 50.3 | percentage of participants | |
| Percentage of Participants With Clinical Remission Through Week 52 | Adalimumab | Week 16 | 60.0 | percentage of participants | |
| Percentage of Participants With Clinical Remission Through Week 52 | Ustekinumab | Week 16 | 57.1 | percentage of participants | |
| Percentage of Participants With Clinical Remission Through Week 52 | Adalimumab | Week 24 | 66.2 | percentage of participants | |
| Percentage of Participants With Clinical Remission Through Week 52 | Ustekinumab | Week 24 | 57.6 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03464136/results